🇺🇸 Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin in United States

FDA authorised Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin on 29 September 1952

Marketing authorisations

FDA — authorised 29 September 1952

  • Application: NDA008662
  • Marketing authorisation holder: SANDOZ
  • Local brand name: NYDRAZID
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA

  • Application: NDA008392
  • Marketing authorisation holder: BRISTOL MYERS SQUIBB
  • Local brand name: NYDRAZID
  • Indication: TABLET — ORAL
  • Status: approved

Read official source →

Other Infectious Disease approved in United States

Frequently asked questions

Is Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin approved in United States?

Yes. FDA authorised it on 29 September 1952; FDA has authorised it.

Who is the marketing authorisation holder for Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin in United States?

SANDOZ holds the US marketing authorisation.